ArticleLife (Basel, Switzerland)2025
Beyond Daily Values: Are Day-to-Day and Albumin-Adjusted Ratios of IL-6, PCT, and CRP Better Predictors of Ventilator-Associated Pneumonia?
Article in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVentilator-associated pneumonia (VAP) is a frequent complication in neurosurgical intensive care patients. This leads to prolonged mechanical ventilation, increased 30-day mortality rates, and extended hospital stays. However, early diagnosis remains a challenge. Biomarkers, such as IL-6, PCT, and CRP, are considered a cornerstone for recognizing VAP and initiating early treatment. Only a very limited number of studies have compared IL-6, PCT, and CRP, focusing on day-to-day dynamics and their albumin ratios. Therefore, we investigated whether, compared with their daily levels, the day-to-day dynamics and albumin-adjusted ratios of IL-6, PCT, and CRP offer improved diagnostic value for VAP. Second, we investigated these biomarkers in patients treated for VAP who did not meet the criteria for VAP.
methodsIn this exploratory, matched case-control study, we investigated 171 neurosurgical ICU patients. Daily biomarker levels, their dynamics, and ratios to serum albumin were assessed beginning four days before VAP. Logistic regression and receiver operating curve (ROC) analyses were performed to evaluate the association between each biomarker and VAP.
resultsIL-6 and its day-to-day dynamics demonstrated the largest differences between VAP patients and nonVAP patients (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.